Compare NiSource Inc Common Stock (NI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NiSource Inc Common Stock vs Tango Therapeutics Inc. — how do they compare? NiSource Inc Common Stock trades at $41.35 (market cap $19.90B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: NiSource Inc Common Stock is far larger — about 5.3× Tango Therapeutics Inc.'s market cap, and NiSource Inc Common Stock pays a 2.89% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold NiSource Inc Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| NI | TNGX | |
|---|---|---|
Market Cap | $19.90B | $3.75B |
Volume | 3,295,580 | 9,619,106 |
Sector | Utilities | Health |
52-Week High | $49.08 | $32.90 |
52-Week Low | $39.00 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $37.23B | $2.77B |
Dividend Yield | 2.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NiSource (NI) trades at $41.49, up 0.63% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 28, 2026. Fundamentals show solid profitability with a 13.15% net income margin and a P/E of 22.07. Recent news highlights dividend declarations and institutional buying interest, though the stock faces headwinds from storm recovery costs and interest rate sensitivity.
The outlook remains positive given analyst consensus with a $49.57 price target and 73% buy ratings. Key opportunities include data center demand growth and regulatory support, while risks involve volatile cash flows, high debt levels, and potential earnings pressure from operational disruptions. Investors should weigh the stable dividend yield against execution risks in a rising rate environment.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About NiSource Inc Common Stock
NiSource is an energy holding company whose regulated subsidiaries provide natural gas and electricity services. Its business is organized around gas distribution and electric operations in the United States.
Read more on NI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
